Articles

47 percent of youth-onset type 2 diabetes can be attributed to prenatal (before birth) exposure to maternal diabetes and obesity.

Both a low-carbohydrate diet or a Mediterranean-style diet may be “effective alternatives” to a low-fat diet, with more favorable effects on lipids and glycemic control, published in last weeks’ New England Journal of Medicine. 

New findings from Bristol scientists could lead to future treatments to prevent lower limb amputations in diabetes.

A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complications, a new study shows.

A new therapy developed at Cedars-Sinai Medical Center improves transplant rates and outcomes for patients awaiting living- and deceased-donor kidney transplantation, according to a study published in the July 17 issue of the New England Journal of Medicine.

A review of studies reveals that the newer, long-acting insulin medications offer only a slight benefit over NPH in terms of blood glucose control in type 1 diabetes. Researchers did see a clear benefit of long-acting insulin in reducing the risk for hypoglycemia, particularly at night.

New research shows that some sweeteners, especially date sugar and dark brown sugars, contain antioxidants that have the potential to control diabetes-linked heart disease and high blood pressure. Some sweeteners used in the study also had the ability to inhibit the activity of a key enzyme related to Type 2 …

The finding comes from a systematic review of 13 observational studies looking at the link between diabetes and TB over the past four decades.

Community-based health programs aimed at diet, exercise, smoking prevention and other known risk factors for chronic diseases could cut health-care costs in the United States by $16 billion a year, at a cost of 10 dollars per patient/year, a new report says.

Biodel announced that its two pivotal Phase III VIAject(TM) clinical trials are now complete. The full trial results will be released either at Biodel’s poster presentation at the European Association for the Study of Diabetes (EASD) on Tuesday, September 9, 2008, or at a later appropriate scientific forum.